Ergoteles LLC Nymox Pharmaceutical Corp Transaction History

Ergoteles LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$1.21 - $2.0 $122,611 - $202,664	-101,332 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.95 - $2.1 $79,420 - $175,562	-83,601 Reduced 45.21%	101,332 $132,000
Q3 2021 Nov 15, 2021	SELL	$1.3 - $2.23 $1,660 - $2,847	-1,277 Reduced 0.69%	184,933 $381,000
Q2 2021 Aug 12, 2021	BUY	$1.46 - $2.48 $271,866 - $461,800	186,210 New	186,210 $294,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.